Is ATNM or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Enlivex Therapeutics N/A 248.08% 206.39%

Is ATNM or ONCY more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Oncolytics Biotech N/A -2,185.97% -321.54%

Is ATNM or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Black Diamond Therapeutics N/A -30.18% -23.91%

Is ATNM or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Polaryx Therapeutics N/A N/A N/A

Is ATNM or KLRS more profitable?

Kalaris Therapeutics' return on equity of -72.78% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Kalaris Therapeutics N/A -72.78% -43.49%

Actinium Pharmaceuticals (ATNM) Competitors

$0.88 -0.04 (-4.22%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$0.89 +0.01 (+0.57%)

As of 07/20/2026 07:34 PM Eastern

Compare

ATNM vs. ENLV, ONCY, BDTX, PLYX, and KLRS

Should you buy Actinium Pharmaceuticals stock or one of its competitors? MarketBeat compares Actinium Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Actinium Pharmaceuticals include Enlivex Therapeutics (ENLV), Oncolytics Biotech (ONCY), Black Diamond Therapeutics (BDTX), Polaryx Therapeutics (PLYX), and Kalaris Therapeutics (KLRS). These companies are all part of the "pharmaceutical products" industry.

How does Actinium Pharmaceuticals compare to Enlivex Therapeutics?

Actinium Pharmaceuticals (NYSE:ATNM) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

In the previous week, Enlivex Therapeutics had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 0 mentions for Actinium Pharmaceuticals. Enlivex Therapeutics' average media sentiment score of 0.25 beat Actinium Pharmaceuticals' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Enlivex Therapeutics	Neutral

Actinium Pharmaceuticals has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Enlivex Therapeutics has lower revenue, but higher earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	307.82	-$48.82M	-$0.75	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Actinium Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 466.25%. Enlivex Therapeutics has a consensus target price of $247.50, indicating a potential upside of 5,234.05%. Given Enlivex Therapeutics' higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enlivex Therapeutics' return on equity of 248.08% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Enlivex Therapeutics	N/A	248.08%	206.39%

Summary

Enlivex Therapeutics beats Actinium Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Oncolytics Biotech?

Actinium Pharmaceuticals (NYSE:ATNM) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Actinium Pharmaceuticals has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Oncolytics Biotech has lower revenue, but higher earnings than Actinium Pharmaceuticals. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	307.82	-$48.82M	-$0.75	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Actinium Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 466.25%. Oncolytics Biotech has a consensus target price of $8.50, suggesting a potential upside of 900.00%. Given Oncolytics Biotech's higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Actinium Pharmaceuticals' return on equity of -100.85% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

In the previous week, Oncolytics Biotech had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for Oncolytics Biotech and 0 mentions for Actinium Pharmaceuticals. Oncolytics Biotech's average media sentiment score of 0.50 beat Actinium Pharmaceuticals' score of 0.00 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Oncolytics Biotech	Neutral

Summary

Oncolytics Biotech beats Actinium Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Black Diamond Therapeutics?

Actinium Pharmaceuticals (NYSE:ATNM) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 0 mentions for Actinium Pharmaceuticals. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Actinium Pharmaceuticals' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Black Diamond Therapeutics	Positive

Actinium Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 466.25%. Black Diamond Therapeutics has a consensus price target of $9.83, suggesting a potential upside of 443.28%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Black Diamond Therapeutics has higher revenue and earnings than Actinium Pharmaceuticals. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	307.82	-$48.82M	-$0.75	N/A
Black Diamond Therapeutics	$70M	1.48	$22.37M	-$0.77	N/A

Actinium Pharmaceuticals has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.25, suggesting that its share price is 225% more volatile than the broader market.

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Black Diamond Therapeutics' return on equity of -30.18% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

Summary

Black Diamond Therapeutics beats Actinium Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Polaryx Therapeutics?

Actinium Pharmaceuticals (NYSE:ATNM) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Polaryx Therapeutics had 4 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 4 mentions for Polaryx Therapeutics and 0 mentions for Actinium Pharmaceuticals. Polaryx Therapeutics' average media sentiment score of 0.23 beat Actinium Pharmaceuticals' score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Polaryx Therapeutics	Neutral

Polaryx Therapeutics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Polaryx Therapeutics	N/A	N/A	N/A

Polaryx Therapeutics has lower revenue, but higher earnings than Actinium Pharmaceuticals. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	307.82	-$48.82M	-$0.75	N/A
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A

Actinium Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 466.25%. Polaryx Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 276.11%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Actinium Pharmaceuticals is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Actinium Pharmaceuticals and Polaryx Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Kalaris Therapeutics?

Actinium Pharmaceuticals (NYSE:ATNM) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

In the previous week, Kalaris Therapeutics had 4 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 4 mentions for Kalaris Therapeutics and 0 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled Kalaris Therapeutics'average media sentiment score.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Kalaris Therapeutics	Neutral

Kalaris Therapeutics' return on equity of -72.78% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Kalaris Therapeutics	N/A	-72.78%	-43.49%

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Actinium Pharmaceuticals has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Actinium Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 466.25%. Kalaris Therapeutics has a consensus target price of $15.60, indicating a potential upside of 290.00%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Actinium Pharmaceuticals is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Kalaris Therapeutics has lower revenue, but higher earnings than Actinium Pharmaceuticals. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	307.82	-$48.82M	-$0.75	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

Summary

Kalaris Therapeutics beats Actinium Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Actinium Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATNM vs. The Competition

Export

Metric	Actinium Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$27.70M	$789.95M	$6.89B	$23.42B
Dividend Yield	N/A	4.84%	2.67%	4.16%
P/E Ratio	-0.64	1.50	27.06	30.65
Price / Sales	307.82	111.87	517.51	20.36
Price / Cash	N/A	22.05	26.68	18.81
Price / Book	0.67	8.67	10.66	4.74
Net Income	-$48.82M	-$3.14M	$3.60B	$1.07B
7 Day Performance	-1.35%	-2.97%	-1.23%	-0.42%
1 Month Performance	-14.27%	0.74%	1.10%	0.69%
1 Year Performance	-47.75%	28.18%	23.65%	16.45%

Actinium Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATNM Actinium Pharmaceuticals	1.8543 of 5 stars	$0.88 -4.2%	$5.00 +466.3%	-48.4%	$27.70M	$90K	N/A	30	Gap Down
ENLV Enlivex Therapeutics	1.6462 of 5 stars	$6.05 -9.3%	$247.50 +3,990.9%	-74.0%	$112.33M	N/A	N/A	70	News Coverage
ONCY Oncolytics Biotech	2.7386 of 5 stars	$0.91 -2.2%	$8.50 +835.9%	-33.1%	$110.87M	N/A	N/A	30	News Coverage
BDTX Black Diamond Therapeutics	3.9917 of 5 stars	$1.86 -2.1%	$9.83 +428.7%	-42.2%	$108.87M	$70M	N/A	90	Positive News
PLYX Polaryx Therapeutics	3.5242 of 5 stars	$2.26 +2.7%	$8.50 +276.1%	N/A	$106.29M	N/A	N/A	11

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ATNM) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. ENLV, ONCY, BDTX, PLYX, and KLRS

How does Actinium Pharmaceuticals compare to Enlivex Therapeutics?

Summary

How does Actinium Pharmaceuticals compare to Oncolytics Biotech?

Summary

How does Actinium Pharmaceuticals compare to Black Diamond Therapeutics?

Summary

How does Actinium Pharmaceuticals compare to Polaryx Therapeutics?

Summary

How does Actinium Pharmaceuticals compare to Kalaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. ENLV, ONCY, BDTX, PLYX, and KLRS

How does Actinium Pharmaceuticals compare to Enlivex Therapeutics?

Does the media prefer ATNM or ENLV?

Which has more volatility & risk, ATNM or ENLV?

Which has preferable earnings and valuation, ATNM or ENLV?

Do insiders and institutionals believe in ATNM or ENLV?

Do analysts rate ATNM or ENLV?

Is ATNM or ENLV more profitable?

Summary

How does Actinium Pharmaceuticals compare to Oncolytics Biotech?

Do insiders & institutionals hold more shares of ATNM or ONCY?

Which has more volatility and risk, ATNM or ONCY?

Which has stronger earnings and valuation, ATNM or ONCY?

Do analysts recommend ATNM or ONCY?

Is ATNM or ONCY more profitable?

Does the media prefer ATNM or ONCY?

Summary

How does Actinium Pharmaceuticals compare to Black Diamond Therapeutics?

Does the media prefer ATNM or BDTX?

Do analysts prefer ATNM or BDTX?

Which has better valuation & earnings, ATNM or BDTX?

Which has more volatility and risk, ATNM or BDTX?

Do insiders and institutionals have more ownership in ATNM or BDTX?

Is ATNM or BDTX more profitable?

Summary

How does Actinium Pharmaceuticals compare to Polaryx Therapeutics?

Does the media favor ATNM or PLYX?

Is ATNM or PLYX more profitable?

Which has higher earnings and valuation, ATNM or PLYX?

Do analysts prefer ATNM or PLYX?

Do institutionals & insiders have more ownership in ATNM or PLYX?

Summary

How does Actinium Pharmaceuticals compare to Kalaris Therapeutics?

Does the media favor ATNM or KLRS?

Is ATNM or KLRS more profitable?

Do institutionals & insiders believe in ATNM or KLRS?

Which has more risk & volatility, ATNM or KLRS?

Do analysts rate ATNM or KLRS?

Which has better valuation and earnings, ATNM or KLRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools